In the September issue of Pharmaceutical Executive, Lev Gerlovin addresses four main questions that US drugmakers must answer to cope with the evolving payer landscape given rising drug prices. To read the article, click the link below.
Assessing physician practices and expectations in the post-COVID era
The ongoing COVID-19 pandemic has affected the routines of many practicing physicians, including an impact on their prescribing decisions. For many physician...